Showing results (11-20 of 61) with videos related to

Sort By:
Pageof 7
Plos One|November 12, 2021
Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in SpainSimone Rivolo, Manuela Di Fusco, Carlos Polanco, et al.
Journal of Medical Economics|September 13, 2022
Public health impact of booster vaccination against COVID-19 in the UK during Delta variant dominance in autumn 2021Diana Mendes, Ruth Chapman, Peter Gal, et al.
Expert Review of Vaccines|December 15, 2022
Public health impact of UK COVID-19 booster vaccination programs during Omicron predominanceDiana Mendes, Ruth Chapman, Elena Aruffo, et al.
Journal of Medical Economics|March 17, 2026
The full value of mRNA seasonal influenza and endemic-stage COVID-19 combination vaccines: a taxonomyJ P Sevilla, Joseph S Knee, Daria Burnes, et al.
Advances in Therapy|December 17, 2022
Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and MultimorbidityAmol D Dhamane, Mauricio Ferri, Allison Keshishian, et al.
Journal of Thrombosis and Thrombolysis|August 2, 2023
Geographic variation in clinical outcomes and anticoagulation among medicare beneficiaries with non-valvular atrial fibrillationBrett D Atwater, Manuela Di Fusco, Allison Keshishian, et al.
BMJ Global Health|September 7, 2024
The global health and economic value of COVID-19 vaccinationJ P Sevilla, Daria Burnes, Joseph S Knee, et al.
Journal of Medical Economics|July 11, 2026
Evaluation of long-term healthcare utilization and costs associated with COVID-19 among adults and children in the USAlon Yehoshua, Rachel M Black, Manuela Di Fusco, et al.
Plos One|March 25, 2026
Assessment of long COVID symptom burden in patients testing positive for SARS-CoV-2 at a nationwide retail pharmacyXiaowu Sun, Joseph C Cappelleri, Laura L Lupton, et al.
Journal of Medical Economics|October 21, 2024
Health outcomes and economic burden among patients with a COVID-19-associated hospitalization in the United States during the predominance of the XBB and JN.1 omicron lineagesAlon Yehoshua, Angela D Cook, Manuela Di Fusco, et al.
Pageof 7